(Eating Well on GLP-1s: Simple and Satisfying)
Abstract Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D)
This paper focuses on serious adverse event reporting in palliative care non-pharmaceutical trials as there is a lack of guidance for researchers
The highly concentrated powder is very economical, neutral in taste and smell, and well accepted by both dogs and cats
washout Timeline 1: Immediate switch (most common) Day 0: Last Wegovy injection Day 7: First Zepbound injection (2.5 mg or higher per provider instruction) Day 14: Second Zepbound injection Weeks 5, 9, 13, etc.: Dose increases per titration schedule This approach maintains continuous GLP-1 receptor agonism
It is also often used to create liposomes , small spheres surrounded by phospholipid bi-layer designed to carry some active ingredient and help its absorption